Comparative Pharmacology
Head-to-head clinical analysis: BACTROBAN versus LUMI SPORYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTROBAN versus LUMI SPORYN.
BACTROBAN vs LUMI-SPORYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
LUMI-SPORYN is a synthetic antimicrobial that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, leading to impaired cross-linking of peptidoglycan and osmotic lysis. It also exhibits concentration-dependent bactericidal activity.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
1000 mg IV every 8 hours over 1 hour for adults with normal renal function.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
6-8 hours; prolonged to 15-30 hours in severe renal impairment (CrCl <30 mL/min)
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Renal 70-80% unchanged, biliary/fecal 20-30%
Category C
Category C
Topical Antibiotic
Topical Antibiotic